ABCL (AbCellera Biologics) ROC (Joel Greenblatt) %: -45.69% (As of Mar. 2026)


ABCL AbCellera Biologics Inc ABCL
59 GF Score
Price $8.18
GF Value $5.62
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is AbCellera Biologics ROC (Joel Greenblatt) %?

AbCellera Biologics ABCL +10.84% 59 ROC (Joel Greenblatt) % is -45.69% as of Mar. 2026. GuruFocus rates ABCL with a GF Score™ of 59/100 and a GF Value™ of $5.62 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,325 Biotechnology companies, AbCellera Biologics ranks better than 68% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. AbCellera Biologics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -45.69%.

The historical rank and industry rank for AbCellera Biologics's ROC (Joel Greenblatt) % or its related term are showing as below:

ABCL' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -95.89   Med: -9.41   Max: 230.97
Current: -45.58

During the past 8 years, AbCellera Biologics's highest ROC (Joel Greenblatt) % was 230.97%. The lowest was -95.89%. And the median was -9.41%.

ABCL's ROC (Joel Greenblatt) % is ranked better than
68% of 1325 companies
in the Biotechnology industry
Industry Median: -297.52 vs ABCL: -45.58

AbCellera Biologics's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


AbCellera Biologics  (NAS:ABCL) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


AbCellera Biologics ROC (Joel Greenblatt) % Related Terms


AbCellera Biologics ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for AbCellera Biologics's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AbCellera Biologics ROC (Joel Greenblatt) % Chart

AbCellera Biologics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial 138.27 112.30 -88.35 -95.89 -50.22

AbCellera Biologics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -67.85 -46.22 -66.10 -22.11 -45.69

ABCL vs AGIO, KOD, IMNM: ROC (Joel Greenblatt) % Comparison

For the Biotechnology subindustry, AbCellera Biologics's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AbCellera Biologics ROC (Joel Greenblatt) % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AbCellera Biologics's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where AbCellera Biologics's ROC (Joel Greenblatt) % falls into.


ABCL
59GF Score
AbCellera Biologics Inc ABCL
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AbCellera Biologics ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(58.293 + 6.336 + 34.67) - (35.983 + 22.509 + 1.4210854715202E-14)
=40.807

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(36.761 + 7.86 + 36.279) - (24.734 + 16.691 + 0)
=39.475

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of AbCellera Biologics for the quarter that ended in Mar. 2026 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-212.72/( ( (428.003 + max(40.807, 0)) + (422.806 + max(39.475, 0)) )/ 2 )
=-212.72/( ( 468.81 + 462.281 )/ 2 )
=-212.72/465.5455
=-45.69 %

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of -45.69% mean?
AbCellera Biologics (ABCL) has a ROC (Joel Greenblatt) % of -45.69% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on AbCellera Biologics and its competitors. According to the industry distribution chart, AbCellera Biologics ranks #424 out of 1325 companies in the Biotechnology industry, placing it in the top 32%.
Is AbCellera Biologics' ROC (Joel Greenblatt) % too high?
AbCellera Biologics' current ROC (Joel Greenblatt) % is -45.69%. Based on the distribution chart, AbCellera Biologics ranks #424 out of 1325 companies in the Biotechnology industry, which is above the industry midpoint. Overall, AbCellera Biologics has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbCellera Biologics' ROC (Joel Greenblatt) % compare to AGIO and KOD?
According to the Biotechnology industry distribution chart, AbCellera Biologics ranks #424 out of 1325 companies for ROC (Joel Greenblatt) %. This puts AbCellera Biologics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on AbCellera Biologics and its competitors. AbCellera Biologics's current ROC (Joel Greenblatt) % is -45.69%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbCellera Biologics stock overvalued right now?
Based on GuruFocus' analysis, AbCellera Biologics (ABCL) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.62, compared to a current price of $8.18 — trading 45.6% above its estimated fair value. The current ROC (Joel Greenblatt) % is -45.69%. AbCellera Biologics' overall GF Score™ is 59/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For AbCellera Biologics (ABCL), the current ROC (Joel Greenblatt) % is -45.69% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AbCellera Biologics (ABCL) Overvalued in 2026?

Based on GuruFocus' analysis, AbCellera Biologics stock appears to be overvalued. The current stock price of $8.18 is trading 45.6% above its estimated GF Value™ of $5.62. GuruFocus considers AbCellera Biologics to be Significantly Overvalued.

Key valuation signals for ABCL:

  • ROC (Joel Greenblatt) %: -45.69%
  • GF Value™: $5.62 vs. price of $8.18 (45.6% above fair value)
  • GF Score™: 59/100 with 5 warning signs

No single metric tells the full story. See the ABCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AbCellera Biologics Business Description

Other Exchanges 8QQ:Germany
Address 150 W 4th Avenue, Vancouver, BC, CAN, V5Y 1G6
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
59GF Score

Get the complete analysis for ABCL

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.18
Price
$5.62
GF Value